SG3 Management’s Neurocrine Biosciences NBIX Stock Holding History

SG3 Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-27,000	Closed	-$2.63M	–	1156
2021 Q2	$2.63M	Sell	27,000 -40,000	-60%	-$3.83M	0.09%	248
2021 Q1	$6.52M	Buy	67,000 +52,000	+347%	+$5.45M	0.16%	134
2020 Q4	$1.44M	Sell	15,000 -16,400	-52%	-$1.58M	0.03%	470
2020 Q3	$3.02M	Buy	31,400 +23,900	+319%	+$2.76M	0.11%	206
2020 Q2	$915K	Buy	+7,500	New	+$829K	0.06%	300

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

SG3 Management's NBIX Position: Q3 2021 in Review

SG3 Management sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 8,500 shares — an estimated $827K sold.

SG3 Management first reported a position in NBIX in Q2 2020 and held it in 4 quarters. The position peaked at $2.43M in Q1 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

SG3 Management reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 8,500 Neurocrine Biosciences shares in Q3 2021, an estimated $827K.
SG3 Management first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 4 quarters.
SG3 Management's Neurocrine Biosciences position peaked at $2.43M in Q1 2021.
395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.